Purity assay is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-05. Numbers and descriptions here follow the published literature rather than marketing material.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and copper(II). The peptide sequence consists of glycine, histidine, and lysine, and its imidazole and amino groups provide binding sites for the metal ion. In the complex, copper is held through nitrogen donors from the histidine side chain, the N-terminal amine, and deprotonated amide nitrogens. The resulting compound is intensely blue and water-soluble. It occurs naturally in human plasma, saliva, and urine at low concentrations.
The peptide was first isolated from human albumin in 1973 by Loren Pickart, who later described its copper-binding behavior. Early work linked the complex to wound healing and tissue remodeling. Plasma levels of GHK decline with age, a pattern that stimulated interest in topical and supplemental applications. Researchers have reported that the tripeptide influences collagen synthesis, antioxidant defense, and inflammatory signaling in cell and animal models. Human clinical evidence remains limited and often relies on small studies.
Commercial products list GHK-Cu as copper tripeptide-1, a cosmetic ingredient. Formulators value its blue color and water solubility, which allow incorporation into serums, creams, and masks. Regulatory treatment varies: in the United States it appears in cosmetics, while some jurisdictions classify certain claims as drug-like. The compound is not an approved drug for any indication. Studies continue to examine its effects on skin, hair, and wound repair, but dosage, delivery, and long-term safety questions remain open.
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
Dry material is normally held cold, commonly at -20 °C for long-term storage and 2 to 8 °C for working quantities, protected from light and moisture. Vials should be allowed to reach room temperature before opening so that condensation does not form on the powder. In liquid formulations the complex is generally kept near neutral to slightly acidic pH, because strongly alkaline conditions favour precipitation of copper hydroxide. Antioxidants or chelate-stabilising excipients are often added, though the specific approaches are proprietary and rarely published in detail.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry to confirm the expected mass. Copper content is measured separately by inductively coupled plasma optical emission spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not establish the metal-to-peptide ratio. Visible spectroscopy provides a rapid check on complex integrity through the absorption band in the visible region. Agreement between the peptide assay and the copper assay is the practical test of whether a sample is the intended complex rather than a mixture.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper(II) tripeptide complex | Contains glycyl-histidyl-lysine ligand |
| Peptide sequence | Gly-His-Lys | N-terminal glycine, C-terminal lysine |
| Molecular formula | C14H22CuN6O4 | Commonly cited for the 1:1 complex |
| Appearance | Blue to blue-violet solid | Color arises from copper d-d transitions |
| Solubility | Water-soluble | Also dissolves in some polar solvents |
Solid GHK-Cu is usually supplied as a lyophilized powder and is kept cold and dry. Moisture, light, and repeated temperature cycling shorten its useful life in the laboratory. In aqueous solution the complex undergoes slow hydrolysis of the peptide backbone and gradual loss of coordinated copper. Buffers containing strong chelators, such as EDTA, compete for the metal and strip it from the peptide. Working solutions are therefore prepared shortly before use, and leftover liquid is not returned to the stock container.
Identity and purity are established with a combination of chromatographic and spectroscopic techniques. Reversed-phase high-performance liquid chromatography separates the intact complex from peptide fragments and free copper, and the elution profile yields a purity estimate. Mass spectrometry gives the mass of the intact species and exposes degradation products. Ultraviolet-visible spectroscopy displays a broad absorption band in the visible region that is characteristic of the copper center. Nuclear magnetic resonance is less informative here, because the paramagnetic metal broadens signals and complicates spectral interpretation.
The peptide portion consists of three amino acids: glycine, histidine and lysine. Copper(II) coordinates through the imidazole nitrogen of histidine, the alpha-amino group of glycine and a deprotonated amide nitrogen of the backbone, producing a roughly square-planar geometry. This arrangement gives the complex its characteristic blue-to-violet colour and helps it resist dissociation in water. Reported stability constants are high, although values differ between studies because of differences in ionic strength and measurement method.
The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.
The melting point was calculated as 284 ± 50 K (11 ± 50 °C), so that flerovium is probably a liquid at room temperature, although the boiling point was not determined. The electron of a hydrogen-like flerovium ion (Fl113+; remove all but one electron) is expected to move so fast that its mass is 1.79 times that of a stationary electron, due to relativistic effects. (The figures for hydrogen-like lead and tin are expected to be 1.25 and 1.073 respectively.) Flerovium would form weaker metal–metal bonds than lead and would be adsorbed less on surfaces.
Since 28 February 2026, the United States and Israel have been at war with Iran and its regional allies. The war follows the Twelve-Day War in June 2025 and sporadic fighting during the Middle Eastern crisis sparked by the Gaza war (2023–present). Amid ongoing US–Iran negotiations regarding Iran's nuclear program, the war began when the US and Israel conducted hundreds of air strikes on targets across Iran, including strikes that assassinated Supreme Leader Ali Khamenei alongside several other Iranian officials. American rationale for initiating the war included regime change, preventing Iran from obtaining a nuclear weapon, a response to the massacre of several if not tens of thousands of anti-government protesters in Iran, and taking Iran's oil and gas resources. Critics have rejected these justifications, maintaining that the attack initiated a war of aggression, in violation of international law. Later war goals focused on nuclear negotiations and reopening the Strait of Hormuz. Public opinion was opposed to the war in the United States and in many other countries, leading to widespread disapproval for Donald Trump and declining views of the US and Israel around the world. The war was preceded in January–February 2026 by the largest US military buildup in the region since the 2003 invasion of Iraq.
(2026) present virtually reconstructed models of the face of the same individual. Choudhary et al. (2026) provided new paleomagnetic and stratigraphic data for the Ramnagar region of India, re-dating its primate-yielding localities to 13.03–11.59 Ma and extending the known chronological range of the primates like Sivapithecus, Kapi and Ramadapis by approximately 200,000 years. Evidence from the study of the cranial endocast of Rudapithecus hungaricus, indicative of presence of sulcal patterns similar to those seen in gorillas, is presented by Assance, Silcox & Begun (2026). Spassov et al. (2026) report the discovery of a nearly complete femur of cf. Graecopithecus from the Miocene strata from the Azmaka-6 locality near Chirpan (Bulgaria), sharing morphological traits with both quadrupeds and bipeds, and interpreted as indicative of a transitional locomotor repertoire including both terrestrial quadrupedalism and an early form of facultative bipedalism. Evidence from the study of teeth and the bony labyrinth of Oreopithecus bambolii, interpreted as indicating that the studied primate was more likely to be a derived stem hominoid than a close relative of Miocene apes from Europe or gibbons, is presented by Urciuoli et al. (2026). Jansma & Locke (2026) interpret Xenopithecus koruensis as a valid basal hominoid taxon distinct from Proconsul africanus. Williams et al.
Sources: en.wikipedia.org
Van Buren (1829), member of New York State Assembly Henry Ledyard (1830), mayor of Detroit; president of Newport Hospital Henry Nicoll (1830), U.S. congressman from New York Henry C. Murphy (1830), U.S. congressman from New York; former U.S. ambassador to the Netherlands John L. O'Sullivan (1831), US minister to Portugal; journalist who coined the term " Manifest Destiny"; publisher of The United States Magazine and Democratic Review James William Beekman (1834), member of the New York State Senate; vice-president of the New York Hospital Isaac C. Delaplaine (1834), U.S. congressman from New York John Richardson Thurman (1835), U.S. congressman from New York John Jay (1836), grandson of Chief Justice John Jay; United States minister to Austro-Hungary; president of the American Historical Association John Vanderbilt (1837), judge, member of the New York State Senate William Ward Duffield (1841), officer, member of the Michigan Senate, superintendent of the U.S. National Geodetic Survey Abram Stevens Hewitt (1842), former mayor of New York City and planner of the first line of the New York City Subway system; Chairman of the Democratic National Committee 1876–1877, son-in-law of philanthropist Peter Cooper Edward Cooper (1842), former mayor of New York City and son of industrialist Peter Cooper Nicholas B. La Bau (1844), member of the New York State Assembly and the New York State Senate John Winthrop Chanler (1847), U.S. congressman from New York Horace Carpentier (1848), first mayor of Oakland, California and president of the Overland Telegraph Company A.
Sample is received. Sample is checked (to ensure that the sample is sent in the correct container for the specimen). Patient's details checked and matched on both form and sample (non-matching samples and/or forms rejected). Sample and form labelled with unique identifying number (UIN). Tests requested on form receipted onto UIN on computer system. Samples placed either on pre-analytical system by MLA or analysed immediately by BMS (dependent on test requested). UIN attached to patient using patient identifying details on form. MLA's also deal with all sample queries and give low level advice to clinical staff on sample acceptance and correct sampling method. They may also do minor upkeep on the pre-analytical systems as well as further upkeep on some point of care analysers — depending on the laboratory in which they are based.
=== Functional selectivity === Some nonbenzodiazepines can be subtype-selective, possibly providing anxiolytic effects with little to no hypnotic or amnesic effects or providing hypnotic effects with little or no anxiolytic effect. Non-sedating anxiolytic drugs derived from the same structural families as the Z-drugs have been developed, such as alpidem, indiplon, pagoclone and suriclone. A number of non-sedating benzodiazepine anxiolytics such as imidazenil and clobazam also exist, with the caveat that neither is a traditional 1,4-benzodiazepine. The functional selectivity is not unique to the nonbenzodiazepine structural class and has more to do with selectivity among different types of GABAA receptors or partial agonism, though this structural class does have more drug candidates.
Sources: en.wikipedia.org
GHK is the free tripeptide, while GHK-Cu includes a bound copper(II) ion. The copper complex is the form most often studied for skin and wound-related activity. The two names are sometimes used interchangeably in product labeling, but they refer to distinct chemical species.
Yes, it is found in human plasma, saliva, and urine. Its concentration in plasma tends to decrease with age. This natural presence is one reason researchers have investigated its role in tissue maintenance.
No, GHK-Cu is not an approved drug in major markets. It is widely used as a cosmetic ingredient, where it is listed under names such as copper tripeptide-1. Any therapeutic claims would require separate regulatory review.
Dry powder is best kept cold, dark and sealed, typically at -20 °C for long-term storage or 2 to 8 °C for material in regular use. Vials should be warmed to room temperature before opening to prevent moisture condensing on the contents. Aqueous stock solutions degrade faster and are usually prepared fresh.